This article is more than 5 years old. Information may no longer be current.
Allergan reports 13.7% increase in second-quarter product net sales
Click Here to Manage Email Alerts
IRVINE, Calif. — Allergan reported $1.4 billion in total product net sales for the second quarter, a 13.7% increase from the second quarter of 2010, the company announced in a news release.
Based on constant currency, total net sales for the second quarter increased 9.6% compared with the same period in 2010, the release said.
The diluted earnings per share attributable to stockholders was $0.79, compared with $0.78 in the second quarter of 2010. Non-GAAP diluted earnings per share attributable to stockholders was $0.96, compared with $0.85 reported a year earlier, an increase of 12.9%.
Total specialty pharmaceutical net sales increased 14%, or 10.1% on a constant currency basis, compared with sales reported in the second quarter of 2010.
Total medical device net sales increased 12.2%, or 7% on a constant currency basis, compared with the second quarter last year.
Allergan anticipates total net product sales of $1.26 billion to $1.34 billion for the third quarter and $5.22 billion to $5.37 billion for the full-year 2011. Specialty pharmaceutical net sales for the year are expected to total $4.31 billion to $4.44 billion. Total year-end medical device net sales are projected to reach $910 million to $930 million, the release said.
In addition, the board of directors established a second-quarter dividend of $0.05 per share, payable on Sept. 8 to stockholders of record on Aug. 18.